Home › Companies › BioCryst Pharmaceuticals, Inc. › 2025-2026

BioCryst Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and BioCryst Pharmaceuticals, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
307Asset managers
1,799Fund votes
June 11, 2026Meeting date

Results at a glance

Meeting of June 11, 2026: 6 items on BioCryst Pharmaceuticals, Inc.’s Form 8-K, filed June 12, 2026: 3 elected · 3 approved.

Material dissent

The Incentive Plan Proposal was approved by the following votes: 65% of votes cast Approved Under 80%
The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes: 69% of votes cast Approved Say-on-pay under 70%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BioCryst Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by BioCryst Pharmaceuticals, Inc.

These tallies are BioCryst Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BioCryst Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 11, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Theresa M. Heggie	176,939,696	--	--	6,915,770	--	96%	Elected	—
Elect Director: Amy E. McKee, M.D.	178,820,838	--	--	5,034,628	--	97%	Elected	—
Elect Director: Jon P. Stonehouse	173,944,412	--	--	9,911,054	--	95%	Elected	—
The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026 was approved by the following votes:	210,304,554	7,192,262	396,293	--	--	97%	Approved	—
The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:	126,098,528	56,797,571	959,367	--	34,037,643	69%	Approved	—
The Incentive Plan Proposal was approved by the following votes:	119,765,948	63,275,217	814,301	--	34,037,643	65%	Approved	—

Source: BioCryst Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the BioCryst Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 307 asset managers that disclosed a BioCryst Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Amy E. McKee, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 178,820,838WITHHELD: 5,034,628

Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Amy E. Mckee, M.D.

BioCryst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Amy E. McKee, M.D.”): 178,820,838 for, 5,034,628 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 62,607,167 for, 230,300 withheld, 14 abstained.

FOR

FOR: 62,607,167ABSTAIN: 14WITHHOLD: 230,300

Largest asset managers voting on “Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Amy E. Mckee, M.D.” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	22,295,716	14	0	For
BlackRock	9,609,520	0	0	For
State Street	7,455,833	0	0	For
Fidelity	5,725,028	0	0	For
TIAA	3,595,530	0	0	For
Charles Schwab	2,352,390	0	0	For
Aberdeen	1,960,732	0	0	For
Pacer Funds Trust	1,568,440	0	0	For
First Trust	1,012,177	0	0	For
Invesco	750,281	0	0	For
AMG FUNDS	698,156	0	0	For
Equitable	322,652	0	183,774	Mixed
Principal Exchange-Traded Funds	420,966	0	0	For
Dimensional	388,034	0	0	For
Goldman Sachs	333,308	0	0	For
Voya	322,895	0	0	For
Lincoln Financial	257,810	0	0	For
Virtus	256,833	0	0	For
CLEARWATER INVESTMENT TRUST	234,472	0	0	For
JPMorgan	215,976	0	0	For
Federated Hermes	215,610	0	0	For
Northern Trust	202,239	0	0	For
ProShares	199,540	0	0	For
Putnam	181,722	0	0	For
Bridge Builder Trust	175,458	0	0	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

2. Elect Director: Jon P. Stonehouse

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 173,944,412WITHHELD: 9,911,054

Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Jon P. Stonehouse

BioCryst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jon P. Stonehouse”): 173,944,412 for, 9,911,054 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 62,593,598 for, 243,853 withheld, 29 abstained.

FOR

FOR: 62,593,598ABSTAIN: 29WITHHOLD: 243,853

Largest asset managers voting on “Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Jon P. Stonehouse” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	22,273,871	29	21,829	For
BlackRock	9,609,520	0	0	For
State Street	7,446,115	0	9,718	For
Fidelity	5,725,028	0	0	For
TIAA	3,595,530	0	0	For
Charles Schwab	2,352,390	0	0	For
Aberdeen	1,960,732	0	0	For
Pacer Funds Trust	1,568,440	0	0	For
First Trust	1,012,177	0	0	For
Invesco	750,281	0	0	For
AMG FUNDS	698,156	0	0	For
Equitable	322,652	0	183,774	Mixed
Principal Exchange-Traded Funds	420,966	0	0	For
Dimensional	388,034	0	0	For
Goldman Sachs	333,308	0	0	For
Voya	322,895	0	0	For
Lincoln Financial	257,810	0	0	For
Virtus	256,833	0	0	For
CLEARWATER INVESTMENT TRUST	234,472	0	0	For
JPMorgan	215,976	0	0	For
Federated Hermes	215,610	0	0	For
Northern Trust	202,239	0	0	For
ProShares	199,540	0	0	For
Putnam	181,722	0	0	For
Bridge Builder Trust	175,458	0	0	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

3. Elect Director: Theresa M. Heggie

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 176,939,696WITHHELD: 6,915,770

Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Theresa M. Heggie

BioCryst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Theresa M. Heggie”): 176,939,696 for, 6,915,770 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 62,361,697 for, 475,764 withheld, 20 abstained.

FOR

FOR: 62,361,697ABSTAIN: 20WITHHOLD: 475,764

Largest asset managers voting on “Election of Directors (each to serve until the 2029 Annual Meeting of Stockholders): Theresa M. Heggie” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	22,295,710	20	0	For
BlackRock	9,609,520	0	0	For
State Street	7,455,833	0	0	For
Fidelity	5,725,028	0	0	For
TIAA	3,595,530	0	0	For
Charles Schwab	2,352,390	0	0	For
Aberdeen	1,960,732	0	0	For
Pacer Funds Trust	1,568,440	0	0	For
First Trust	1,012,177	0	0	For
Invesco	750,281	0	0	For
AMG FUNDS	698,156	0	0	For
Equitable	322,652	0	183,774	Mixed
Principal Exchange-Traded Funds	420,966	0	0	For
Dimensional	388,034	0	0	For
Goldman Sachs	333,308	0	0	For
Voya	322,895	0	0	For
Lincoln Financial	228,322	0	29,488	Mixed
Virtus	256,833	0	0	For
CLEARWATER INVESTMENT TRUST	234,472	0	0	For
JPMorgan	0	0	215,976	Withhold
Federated Hermes	215,610	0	0	For
Northern Trust	202,239	0	0	For
ProShares	199,540	0	0	For
Putnam	181,722	0	0	For
Bridge Builder Trust	175,458	0	0	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

4. The Incentive Plan Proposal was approved by the following votes:

Official resultCOMPENSATIONReported outcome: Approved

65% Approved · of votes cast

FOR 65%AGAINST

FOR: 119,765,948AGAINST: 63,275,217

Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE STOCK INCENTIVE PLAN.

BioCryst Pharmaceuticals, Inc.’s own tally for this item (“The Incentive Plan Proposal was approved by the following votes:”): 119,765,948 for, 63,275,217 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Incentive Plan Proposal was approved by the following votes:”
Support: 65% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 76 asset managers below reported 43,014,934 for, 19,723,509 against, 34,298 abstained.

FORAGAINST

FOR: 43,014,934AGAINST: 19,723,509ABSTAIN: 34,298

Largest asset managers voting on “TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANC” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	22,273,717	22,011	1	For
BlackRock	9,609,520	0	0	For
State Street	5,374	7,450,459	0	Against
Fidelity	5,144,361	580,667	0	Mixed
TIAA	0	3,595,530	0	Against
Charles Schwab	2,352,390	0	0	For
Aberdeen	1,960,732	0	0	For
Pacer Funds Trust	0	1,568,440	0	Against
First Trust	0	1,012,177	0	Against
Invesco	0	750,281	0	Against
AMG FUNDS	0	698,156	0	Against
Equitable	322,652	183,774	2,360	Mixed
Principal Exchange-Traded Funds	0	420,966	0	Against
Dimensional	0	388,034	0	Against
Goldman Sachs	0	333,308	0	Against
Voya	0	322,895	0	Against
Lincoln Financial	29,488	228,322	0	Mixed
Virtus	0	256,833	0	Against
JPMorgan	215,976	0	0	For
Federated Hermes	215,610	0	0	For
Northern Trust	0	202,239	0	Against
ProShares	0	199,540	0	Against
Putnam	0	181,722	0	Against
Bridge Builder Trust	143,066	32,392	0	Mixed
ALGER FUNDS	0	155,560	0	Against

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

5. The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

69% Approved · of votes cast

FOR 69%AGAINST

FOR: 126,098,528AGAINST: 56,797,571

Details: description as filed, official tally, votes by 299 asset managers

Description as filed by funds: To hold a non-binding, advisory vote regarding executive compensation.

BioCryst Pharmaceuticals, Inc.’s own tally for this item (“The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”): 126,098,528 for, 56,797,571 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BioCryst Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “COMPENSATION” (2 managers, 320 for); “Say on Pay” (2 managers, 1,237 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 74 asset managers voting on “To hold a non-binding, advisory vote regarding executive compensation.” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	22,295,566	163	2	For
BlackRock	1,005,927	8,603,593	0	Mixed
State Street	7,447,219	8,614	0	For
Fidelity	774,555	4,950,473	0	Mixed
TIAA	3,595,530	0	0	For
Charles Schwab	2,352,390	0	0	For
Aberdeen	1,960,732	0	0	For
Pacer Funds Trust	1,568,440	0	0	For
First Trust	0	1,012,177	0	Against
Invesco	0	750,281	0	Against
AMG FUNDS	698,156	0	0	For
Equitable	2,360	506,426	0	Against
Principal Exchange-Traded Funds	0	420,966	0	Against
Dimensional	0	388,034	0	Against
Goldman Sachs	333,308	0	0	For
Voya	322,895	0	0	For
Lincoln Financial	178,874	78,936	0	Mixed
Virtus	0	256,833	0	Against
JPMorgan	215,976	0	0	For
Federated Hermes	215,610	0	0	For
Northern Trust	0	202,239	0	Against
ProShares	0	199,540	0	Against
Putnam	0	181,722	0	Against
Bridge Builder Trust	93,500	81,958	0	Mixed
ALGER FUNDS	0	155,560	0	Against

Fund voting reports, all 74 managers: 43,742,102 for, 18,990,131 against, 27,219 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 248 asset managers voting on “To hold a non-binding, advisory vote regarding executive compensation.” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Janus Henderson	15,186,732	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	10,862,630	0	For
RA CAPITAL MANAGEMENT, L.P.	9,401,407	0	For
BlackRock	1,737,406	5,462,432	Mixed
GEODE CAPITAL MANAGEMENT, LLC	0	5,677,962	Against
Aberdeen	5,040,670	0	For
State Street	4,381,703	90,146	For
Vestal Point Capital, LP	0	4,158,394	Against
Frazier Life Sciences Management, L.P.	4,009,240	0	For
PERCEPTIVE ADVISORS LLC	3,950,268	0	For
Nuveen	3,693,642	0	For
GW&K Investment Management, LLC	64,980	0	For
Charles Schwab	2,353,492	0	For
Candriam S.C.A.	0	2,286,841	Against
Vanguard	2,015,965	9,959	For
Fisher Asset Management, LLC	0	1,920,526	Against
1919 Investment Counsel, LLC	0	1,804,977	Against
RICE HALL JAMES & ASSOCIATES, LLC	1,784,751	0	For
Northern Trust	0	1,481,788	Against
JUPITER ASSET MANAGEMENT LTD	0	1,464,307	Against
ORBIMED ADVISORS LLC	1,425,200	0	For
Two Sigma	0	1,416,201	Against
Legal & General Investment Management Ltd	1,367,922	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	0	1,257,871	Against
Invesco	0	1,123,455	Against

Institutional-manager reports, all 248 managers: 74,122,000 for, 36,438,242 against, 2,000 abstained, 1,317 not voted, 2,550,474 mixed. Showing the 25 largest; see all in the interactive database.

6. The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 210,304,554AGAINST: 7,192,262

Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 2026.

BioCryst Pharmaceuticals, Inc.’s own tally for this item (“The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026 was approved by the following votes:”): 210,304,554 for, 7,192,262 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposed ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026 was approved by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 75 asset managers below reported 62,639,241 for, 173,381 against, 27,217 abstained.

FOR

FOR: 62,639,241AGAINST: 173,381ABSTAIN: 27,217

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR ” at BioCryst Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	22,283,017	12,711	For
BlackRock	9,609,520	0	For
State Street	7,452,888	2,945	For
Fidelity	5,725,028	0	For
TIAA	3,595,530	0	For
Charles Schwab	2,352,390	0	For
Aberdeen	1,960,732	0	For
Pacer Funds Trust	1,568,440	0	For
First Trust	1,012,177	0	For
Invesco	750,281	0	For
AMG FUNDS	698,156	0	For
Equitable	508,786	0	For
Principal Exchange-Traded Funds	420,966	0	For
Dimensional	388,034	0	For
Goldman Sachs	333,308	0	For
Voya	322,895	0	For
Lincoln Financial	257,810	0	For
Virtus	256,833	0	For
CLEARWATER INVESTMENT TRUST	234,472	0	For
JPMorgan	215,976	0	For
Federated Hermes	215,610	0	For
Northern Trust	202,239	0	For
ProShares	199,540	0	For
Putnam	181,722	0	For
Bridge Builder Trust	175,458	0	For

Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.

Largest BioCryst Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 254,162,660 shares outstanding at the time of that meeting.

Fund voting reports: top BioCryst Pharmaceuticals, Inc. shareholders by shares voted on “To hold a non-binding, advisory vote regarding executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	8.77%
2	BlackRock	3.78%
3	State Street	2.93%
4	Fidelity	2.25%
5	TIAA	1.41%
6	Charles Schwab	0.93%
7	Aberdeen	0.77%
8	Pacer Funds Trust	0.62%
9	First Trust	0.40%
10	Invesco	0.30%

Institutional-manager reports: top BioCryst Pharmaceuticals, Inc. shareholders by shares voted on “To hold a non-binding, advisory vote regarding executive compensation.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Janus Henderson	5.98%
2	DEERFIELD MANAGEMENT COMPANY, L.P.	4.27%
3	RA CAPITAL MANAGEMENT, L.P.	3.70%
4	BlackRock	2.83%
5	GEODE CAPITAL MANAGEMENT, LLC	2.23%
6	Aberdeen	1.98%
7	State Street	1.76%
8	Vestal Point Capital, LP	1.64%
9	Frazier Life Sciences Management, L.P.	1.58%
10	PERCEPTIVE ADVISORS LLC	1.55%

Reported BioCryst Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

BioCryst Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group	8.16%	DEF14A
BlackRock, Inc.	6.88%	DEF14A
RA Capital Management, L.P.	6.23%	13G
RA Capital Healthcare Fund, L.P.	6.02%	DEF14A
STATE STREET CORPORATION	5.98%	13G
Deerfield Mgmt, L.P.	5.64%	13G
Deerfield Partners, L.P.	5.64%	DEF14A
Vanguard Capital Management	5.10%	13G
Jon P. Stonehouse	2.17%	DEF14A
Alane P. Barnes	0.51%	DEF14A

Percentages above are of 254,162,660 shares outstanding, as reported by BioCryst Pharmaceuticals, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BioCryst Pharmaceuticals, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At BioCryst Pharmaceuticals, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 307 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,799 separate fund positions. On the most widely held item on that ballot — To hold a non-binding, advisory vote regarding executive compensation. — BioCryst Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 69% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BioCryst Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

BioCryst Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.